M
mememanw24
Iron
- Joined
- May 7, 2025
- Posts
- 52
- Reputation
- 37
Threads on KY19382:
• KY19382, THE ULTIMATE HEIGHTMAX DRUG — explains the Wnt mechanism and mouse data.
• Literal heightpills 2 (and hair) — mentions KY19382 as a Wnt activator for bone elongation and hair.
• Potential for KY19382 on longitudinal growth (high iq debunkers gtfih) — deep dive on combining with GHRFs/GH.
The KY19382 Connection
KY19382 works by blocking the CXXC5-Dvl interaction, which prevents β-catenin degradation and activates the Wnt pathway → more chondrocyte proliferation, delayed senescence, longer growth plates, and more bone growth. It’s the “holy grail” in theory for heightmaxxing because it directly boosts the signals that FGFR3 tries to suppress.
Now, VPA connects because it’s an HDAC inhibitor that upregulates Wnt/β-catenin too — but through a different mechanism: inhibiting GSK-3β, stabilizing β-catenin, and activating Wnt targets in chondrocytes. It’s basically hitting the same pathway downstream, just less specifically.
Theoretically, VPA is less potent than KY19382 — I’d estimate 50–70% as effective at best for Wnt activation in chondrocytes.
• KY19382 is super targeted (blocks CXXC5-Dvl directly) → stronger, more specific Wnt boost.
• VPA is broader (HDAC inhibition affects many pathways) → weaker on Wnt but still gets the job done indirectly.
From mouse data and cell studies, KY19382 gives bigger chondrocyte proliferation, but VPA has similar (though milder) effects on β-catenin stabilization and bone elongation in models. VPA is like the budget version — not as strong, but way cheaper and available.
• Theoretical height benefits: Upregulates Wnt/β-catenin → more chondrocyte proliferation + delayed growth plate senescence → extra velocity and time before closure (similar to KY19382’s mouse gains).
• Facial aesthetics: Could help maxillary/mandibular remodeling if plates still responsive (Wnt drives craniofacial bone growth too).
• Dose: Low 250–500 mg/day (split doses) — start 250 mg to avoid sides.
• KY19382, THE ULTIMATE HEIGHTMAX DRUG — explains the Wnt mechanism and mouse data.
• Literal heightpills 2 (and hair) — mentions KY19382 as a Wnt activator for bone elongation and hair.
• Potential for KY19382 on longitudinal growth (high iq debunkers gtfih) — deep dive on combining with GHRFs/GH.
The KY19382 Connection
KY19382 works by blocking the CXXC5-Dvl interaction, which prevents β-catenin degradation and activates the Wnt pathway → more chondrocyte proliferation, delayed senescence, longer growth plates, and more bone growth. It’s the “holy grail” in theory for heightmaxxing because it directly boosts the signals that FGFR3 tries to suppress.
Now, VPA connects because it’s an HDAC inhibitor that upregulates Wnt/β-catenin too — but through a different mechanism: inhibiting GSK-3β, stabilizing β-catenin, and activating Wnt targets in chondrocytes. It’s basically hitting the same pathway downstream, just less specifically.
Theoretically, VPA is less potent than KY19382 — I’d estimate 50–70% as effective at best for Wnt activation in chondrocytes.
• KY19382 is super targeted (blocks CXXC5-Dvl directly) → stronger, more specific Wnt boost.
• VPA is broader (HDAC inhibition affects many pathways) → weaker on Wnt but still gets the job done indirectly.
From mouse data and cell studies, KY19382 gives bigger chondrocyte proliferation, but VPA has similar (though milder) effects on β-catenin stabilization and bone elongation in models. VPA is like the budget version — not as strong, but way cheaper and available.
• Theoretical height benefits: Upregulates Wnt/β-catenin → more chondrocyte proliferation + delayed growth plate senescence → extra velocity and time before closure (similar to KY19382’s mouse gains).
• Facial aesthetics: Could help maxillary/mandibular remodeling if plates still responsive (Wnt drives craniofacial bone growth too).
• Dose: Low 250–500 mg/day (split doses) — start 250 mg to avoid sides.
